Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Veradermics Incorporated (MANE)

Veradermics Incorporated (MANE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy Business Wire - Fri Jul 17, 6:30AM CDT

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation...

MANE : 111.32 (+5.19%)
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout Business Wire - Wed Jul 15, 6:00AM CDT

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as...

MANE : 111.32 (+5.19%)
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss Business Wire - Tue Jul 14, 5:54PM CDT

Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET

MANE : 111.32 (+5.19%)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors GlobeNewswire - Tue Jun 2, 7:30AM CDT

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (“Achieve” or the “Company”) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...

MANE : 111.32 (+5.19%)
TARS : 59.85 (+3.74%)
ACHV : 6.27 (+5.20%)
Veradermics to Present at Upcoming June Investor Conferences Business Wire - Thu May 28, 3:30PM CDT

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that...

MANE : 111.32 (+5.19%)
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research Business Wire - Wed May 27, 6:30AM CDT

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that...

MANE : 111.32 (+5.19%)
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium Business Wire - Thu May 14, 6:30AM CDT

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that...

MANE : 111.32 (+5.19%)
Veradermics: Q1 Earnings Snapshot AP - Tue May 12, 4:13PM CDT

Veradermics: Q1 Earnings Snapshot

MANE : 111.32 (+5.19%)
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Business Wire - Tue May 12, 6:30AM CDT

Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years ...

MANE : 111.32 (+5.19%)
Veradermics Announces Pricing of Upsized Public Offering and Private Placement Business Wire - Wed Apr 29, 9:32PM CDT

Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...

MANE : 111.32 (+5.19%)

Barchart Exclusives

Alphabet Is Up 94% and Meta Is Down 5%. Barchart Data Helps Pick the Best AI Dividend Stock to Buy Now. Barchart - Fri Jul 17, 6:00PM CDT
Alphabet’s broader ecosystem gives it the long-term edge, while Meta offers faster growth, a lower valuation and a higher yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.